We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Paxlovid is authorized for treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg. Read More
The bivalent vaccine also elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the Spikevax booster, Moderna said. Read More
Lilly said the drug will be available in the week of Aug.15, before the anticipated depletion of the U.S. government’s currently available supply. Read More